

THE BRITISH JOURNAL OF PSYCHIATRY

December 1993 Vol. 163 Supplement 22

The Psychopharmacology of Schizophrenia

Edited by

Donald Addington and Jean Addington

Published by The Royal College of Psychiatrists

THE BRITISH JOURNAL OF PSYCHIATRY

SUPPLEMENT NUMBER 22

VOLUME 163, 1993

The Psychopharmacology of Schizophrenia

Edited by

DONALD ADDINGTON and JEAN ADDINGTON

Publication of this Supplement was made possible by the kind help of Foothills Hospital Schizophrenia Unit

The British Journal of Psychiatry

Published monthly. Founded in 1853 as the Asylum Journal and known as the Journal of Mental Science from 1855 to 1963

Editor: Greg Wilkinson

Senior Associate Editor Alan Kerr

Associate Editors

Dora Black, Sidney Crown, Julian Leff, Sir Martin Roth, Peter Tyrer

Assistant Editors

Mohammed Abou-Saleh, German Berrios, Peter Bruggen, Patricia Casey, John Cookson, Tom Fahy, Alexander Kellam, Stuart Montgomery, Catherine Oppenheimer, Ian Pullen, Rosalind Ramsay, Henry Rollin, Oliver Russell, George Stein, Stephen Wilson

Corresponding Editors

Sidney Bloch (Australia), Patrice Boyer (France), Brian Cooper (Germany), E. L. Edelstein (Israel), Václav Filip (Czech Republic), Harold Merskey (Canada), Paul Mullen (Australia), Ahmed Okasha (Egypt), Michelle Tansella (Italy), Toma Tomov (Bulgaria), John Tsiantis (Greece), José Vázquez-Barquero (Spain), Richard Warner (USA)

Publications Manager Dave Jago

Scientific Editor Ralph Footring

Bulletin Manager Elaine Millen

^{⊗™} The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences – Permanence of Paper for Printed Library Materials ANS1 Z39. 48–1984.

Typeset by Dobbie Typesetting, Tavistock, Devon. Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD (tel. 0305-251 066).

© 1993 The Royal College of Psychiatrists

Assistant Scientific Editor Marina Holmes

Editorial Assistants

Judy Ashworth, Julia Burnside

Subscriptions

Non-members of the College should contact the British Journal of Psychiatry Subscription Department, The Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE. Annual subscription rates for 1992 (12 issues post free) are as follows:

UK and Europe: institutions: £140, individuals £123 US: institutions \$295,

individuals \$200

Elsewhere: institutions £165, individuals £130

Payment should be made out to the British Journal of Psychiatry.

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 081-642 0162, fax 081-643 2275).

US Mailing Agents: Mercury Airfreight International Ltd, Inc., 2323 Randolph Avenue, Avenel, NJ 07001.

Back issues published before 1988 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent, England (tel. 0303-850-101).

Contents

List of contributors	4
Introduction DONALD ADDINGTON and JEAN ADDINGTON	6
Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development JEFFREY A. LIEBERMAN	7
Metabolism of phenothiazine and butyrophenone antipsychotic drugs. A review of some recent research findings and clinical implications J. W. HUBBARD, K. K. MIDHA, E. M. HAWES, G. MCKAY, S. R. MARDER, M. ARAVAGIRI and E. D. KORCHINSKI	19
Implications of positron emission tomography research for the investigation of the actions of antipsychotic drugs STEPHEN J. LIST and JOHN M. CLEGHORN	25
Dopamine receptors and antipsychotic drug response ROGER K. SUNAHARA, PHILIP SEEMAN, HUBERT H. M. VAN TOL and HYMAN B. NIZNIK	31
Assessing depression in schizophrenia: the Calgary Depression Scale DONALD ADDINGTON, JEAN ADDINGTON and ELEANOR MATICKA-TYNDALE	39
The importance of non-biological factors in influencing the outcome of clinical trials W. GAEBEL	45
Methodological and design issues in clinical trials of new neuroleptics: an overview A. GEORGE AWAD	51
Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis NINA R. SCHOOLER	58
Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications SAMUEL G. SIRIS	66